Prevention of Chest Pain in Chemo-treated Cancer Patients

Last updated: July 5, 2024
Sponsor: Vejle Hospital
Overall Status: Completed

Phase

N/A

Condition

Angina

Myocardial Ischemia

Chest Pain

Treatment

Cardiologic assessment

Clinical Study ID

NCT03486340
CATCH2018
  • Ages > 18
  • All Genders

Study Summary

This is a prospective, exploratory, randomised clinical trial. Patients with diagnosed cancer that are to be treated with 5-fluorouracil (5-FU) will be randomised into standard oncological treatment or a cardiological assessment prior to the 5-FU treatment. The investigators hypothesize that aggressive management of ischemic risk factors in asymptomatic patients will reduce the number of hospitalisations and investigations for acute coronary syndrome during and after 5-FU treatment and that patients with high coronary artery calcium scores are more likely to experience chest pain during the treatment with 5-FU.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Histologically verified cancer

  • First-time treatment with 5-FU/Capecitabine

  • Expected remaining lifetime > 6 months

  • Informed consent

Exclusion

Exclusion Criteria:

  • Known ischemic heart disease

  • Ischemia-suspicious symptoms prior to 5-FU treatment

  • Ischemia-suspicious ECG-changes prior to 5-FU treatment

Study Design

Total Participants: 218
Treatment Group(s): 1
Primary Treatment: Cardiologic assessment
Phase:
Study Start date:
April 11, 2018
Estimated Completion Date:
June 07, 2024

Connect with a study center

  • Departments of Oncology and Medicine, Vejle Hospital

    Vejle,
    Denmark

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.